Sign in
4

Changes in Ownership

Aclaris Therapeutics, Inc. Filed Acc 0001209191-24-002836

Options or other derivatives

  • Chief Financial Officer acquired 413,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Balthaser Kevin Chief Financial Officer 2024-02-01 Grant or award · Employee Stock Option (Right to Buy) +206,500 206,500 D
Balthaser Kevin Chief Financial Officer 2024-02-01 Grant or award · Restricted Stock Units +59,000 59,000 D
Balthaser Kevin Chief Financial Officer 2024-02-01 Grant or award · Restricted Stock Units +147,500 147,500 D
Loading xslF345X05/doc4.xml…